{"filings":[{"id":779716,"accession_number":"0001790340-26-000059","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2026-06-01T20:51:53+00:00","items":["8.01"],"status":"ready","headline":"Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 55-patient ITT population, mOS 17.3 months (cutoff Apr 24, 2026) vs 8.5 months standard of care.","mPFS 8.3 months; ORR 36% (18/50), DCR 82% (41/50) in response-evaluable patients.","84% of evaluable patients maintained or gained weight; Grade ≥3 TEAEs: Anemia 16%, Neutropenia 18%.","Expects first patient dosed in pivotal Phase 3 (MAPKeeper 301) mid-2026; topline data mid-2028.","Plans Phase 1b/2 trial of atebimetinib+Libtayo in NSCLC starting H2 2026; data late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452556,"accession_number":"0001790340-26-000055","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2026-05-15T11:43:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering Q1 net loss $13.5M; cash $198.6M; Phase 3 pancreatic trial recruiting; ASCO data June 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss $13.5M ($0.21 per share) vs $15.0M ($0.42 per share) in Q1 2025.","Cash, equivalents and marketable securities $198.6M (Dec 31, 2025: $217.0M); runway into 2029.","R&D expenses $10.6M (down from $11.5M YoY); G&A expenses $4.7M (up from $4.0M).","Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer now recruiting; first patient dosing mid-2026.","Updated survival data from Phase 2a cohort (55 patients) to be presented in oral session at ASCO June 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108599,"accession_number":"0001790340-26-000040","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $56.0M ($1.27/share), down from $61.0M ($2.04/share) in 2024.","Cash and marketable securities $217.0M as of Dec 31, 2025, with anticipated runway into 2029.","Phase 2a pancreatic cancer data: 64% OS at 12 months for atebimetinib + mGnP, above standard of care 35%.","Pivotal Phase 3 MAPKeeper 301 on track to dose first patient mid-2026; FDA and EMA alignment secured.","Plan to dose first patient in Phase 2 trial of atebimetinib + Libtayo in RAS-mutant NSCLC in 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108598,"accession_number":"0001790340-26-000006","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immuneering reports 64% OS at 12 months in Phase 2a pancreatic cancer trial; median OS not reached","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["64% OS at 12 months (SOC 35%) in 34 first-line pancreatic cancer patients at 320 mg atebimetinib + mGnP; median OS not reached.","Median PFS 8.5 months; 94% OS at 6 months (SOC 67%) and 83% at 9 months (SOC ~47% estimated).","Grade ≥3 TEAEs in ≥10%: anemia (18%) and neutropenia (18%); no Grade 5 events, no new safety signals.","Near-term milestones: Phase 3 enrollment start mid-2026; >50 patient data in H1 2026; NSCLC trial start H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125044,"accession_number":"0001790340-25-000133","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering Q3: 86% 9-month OS in pancreatic cancer; raised $225M; cash into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib + mGnP.","Raised $225M in financing ($175M public offering + $25M Sanofi placement + $25M private placement).","Cash and equivalents $227.6M as of Sep 30, 2025; cash runway extended into 2029.","Granted US composition of matter patent for atebimetinib expiring 2042, with potential term extension.","New case studies show complete response and conversion to curative-intent surgery with atebimetinib + FOLFIRINOX."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141741,"accession_number":"0001104659-25-093436","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Immuneering prices $175M public offering; Sanofi invests $25M in concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 18,959,914 shares at $9.23/share; expected gross ~$175M; net proceeds ~$164.1M.","Sanofi subsidiary Aventis to invest $25M via private placement at same price, 2,708,559 shares.","Combined net proceeds ~$187.4M; cash runway extended into 2029; closing expected Sep 26, 2025.","Company reduced ATM program by $1.25M and suspended sales under that amount.","Proceeds to advance preclinical/clinical development and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141740,"accession_number":"0001104659-25-092957","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Immuneering signs $25M Sanofi placement contingent on public offering; Phase 2a pancreatic data shows 86% OS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanofi subsidiary Aventis agrees to purchase $25M in stock at public offering price; closing contingent on $75M+ public offering by Sept 26, 2025.","Updated Phase 2a atebimetinib + mGnP data in 1L pancreatic cancer (N=34): 86% OS at 9 mos (vs ~47% SOC), median PFS 9.6 mos, median OS not reached.","Safety profile: Grade ≥3 TEAEs in ≥10% were anemia (24%) and neutropenia (18%); no Grade 5 events.","Near-term milestones: regulatory feedback on Phase 3 plans in Q4 2025; potential Phase 3 start by end 2025 and first patient by mid-2026.","Leerink Partners and Oppenheimer & Co. act as joint bookrunners for the public offering and placement agents for private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141739,"accession_number":"0001104659-25-081995","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Immuneering raises $25M in private placement at $3.95/unit, warrants at $5.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$25M gross proceeds from 6.33M shares (or pre-funded warrants) and 2.85M warrants at $5.50.","Combined purchase price of $3.95 per unit, representing a ~15% premium over Aug. 20 close.","Proceeds to support clinical development of atebimetinib in first-line pancreatic cancer.","Closing expected on or about August 26, 2025; registration rights agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141738,"accession_number":"0001790340-25-000102","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering reports Q2 net loss $14.4M; highlights 94% OS at 6 months in pancreatic cancer trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.4M ($0.40/share) vs $14.1M ($0.47/share) in Q2 2024; cash $26.4M as of June 30.","94% overall survival at 6 months in Phase 2a of atebimetinib + mGnP in first-line pancreatic cancer (n=34); median OS not reached.","Third-line pancreatic cancer patient on atebimetinib monotherapy >18 months with confirmed partial response and 34% tumor reduction.","US composition of matter patent granted for atebimetinib provides exclusivity into 2042; pivotal trial expected in 2026.","Cash runway sufficient into 2026; End of Phase 2 meeting request submitted to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159641,"accession_number":"0001790340-25-000077","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immuneering reports interim Phase 2a data: 39% ORR, 81% DCR in first-line pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of May 26, 2025 cutoff: 1 CR, 13 PR (4 pending confirmation), 15 SD among 36 evaluable patients; DCR 81%, ORR 39%.","In 320 mg ITT population (n=34): 94% OS and 72% PFS at 6 months median follow-up; median OS and PFS not reached.","Grade≥3 TEAEs in ≥10% of 320 mg patients: anemia (18%) and neutropenia (15%); no Grade 5 events.","Additional data expected Q4 2025; pivotal trial of atebimetinib+mGnP in 1L pancreatic cancer planned for 2026, pending regulatory feedback Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159640,"accession_number":"0001790340-25-000063","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immuneering annual meeting: all three director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["69.1% of outstanding Class A common stock represented at June 13, 2025 meeting.","Ann E. Berman, Diana F. Hausman, M.D., and Thomas J. Schall, Ph.D. elected as Class I directors.","RSM US LLP ratified as independent auditor for fiscal year ending December 31, 2025.","Broker non-votes of 10,009,639 on director elections; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159639,"accession_number":"0001790340-25-000059","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering reports Q1 2025 results: net loss $15M, positive IMM-1-104 data, CMO named","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.0M ($0.42/sh) vs $14.3M ($0.49/sh) in Q1 2024; R&D expenses $11.5M.","Cash $35.9M as of March 31, 2025; runway extended into 2026.","Positive IMM-1-104 data: 13-month monotherapy PFS in third-line pancreatic cancer; complete response in first-line combo with chemo.","Named Dr. Igor Matushansky as CMO; signed clinical supply agreement with Regeneron for Libtayo combo in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178015,"accession_number":"0001790340-25-000039","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering reports positive Phase 2a data for IMM-1-104 in pancreatic cancer; cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a data: IMM-1-104 + mGnP showed 43% ORR, 86% DCR; + mFFX showed 50% ORR vs historic 23% and 32%.","Planning underway for potential global pivotal trial of IMM-1-104 in first-line pancreatic cancer.","Cash $36.1M at Dec 31, 2024; plus $13.7M from ATM in Jan 2025; runway into 2026.","Named Dr. Igor Matushansky as Chief Medical Officer to lead clinical programs.","Phase 1 pancreatic cancer patient on IMM-1-104 monotherapy for 13+ months with stable disease and 91% CA 19-9 reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178014,"accession_number":"0001790340-25-000014","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immuneering reports 50% ORR in Phase 2a of IMM-1-104/mFFX; raises $13.7M via ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Jan 6, 2025, 3 of 6 evaluable patients achieved partial response, 3 stable disease; 50% ORR per RECIST.","IMM-1-104 with mFFX generally well tolerated; 3 partial responders and 1 stable disease patient remain on treatment.","Raised net proceeds of $13.7M in January 2025 through at-the-market equity offering program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178013,"accession_number":"0001790340-25-000012","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immuneering reports 43% ORR in first-line pancreatic combo; plans new trials in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IMM-1-104 + mGnP in 1L pancreatic: 1 complete response, 2 partial response (43% ORR), 86% DCR among 7 evaluable patients.","IMM-1-104 + mFFX in 1L pancreatic: all 4 patients had tumor shrinkage; 1 partial response with 100% target lesion reduction.","IMM-1-104 monotherapy in 2L pancreatic: 11 of 21 evaluable patients achieved disease control; 1 partial response with 67% reduction.","IMM-6-415 Phase 1 PK/PD: up to 77% pERK inhibition; generally well tolerated with no dose-limiting toxicities.","Additional Phase 2a data expected Q2 2025; plans to launch arms in melanoma and NSCLC with combinations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194704,"accession_number":"0001790340-24-000078","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering Q3 net loss $14.6M; positive initial Phase 2a data for IMM-1-104","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M ($0.49/share) vs $12.6M ($0.43) in Q3 2023; cash $50.7M.","Positive initial Phase 2a data: complete and partial responses with IMM-1-104 + chemo in first-line pancreatic cancer.","FDA granted Orphan Drug and Fast Track designations for IMM-1-104 in pancreatic cancer.","Cash runway into Q4 2025; R&D expenses $11.3M, G&A $4.0M.","Initial data from additional Phase 2a arm and Phase 1 data for IMM-6-415 expected by year end."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194703,"accession_number":"0001790340-24-000073","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K/A","filed_at":"2024-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immuneering appoints Dr. Thomas Schall to Compensation Committee effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Thomas Schall appointed to Compensation Committee of Board, effective Oct 1, 2024.","Previous election as Class I director on March 11, 2024; committee assignment now settled.","Appointment follows recommendation of Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211003,"accession_number":"0001790340-24-000069","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immuneering reports 40% ORR, 80% DCR from IMM-1-104 combo in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient had complete response; second unconfirmed partial; third/fourth stable disease; fifth equivocal progressive disease.","80% disease control rate and 40% overall response rate (RECIST) in first five patients; all remain on treatment.","DSMB approved enrollment of additional patients at 320 mg QD; dosing has begun.","Initial data from another Phase 2a arm of IMM-1-104 and Phase 1 data for IMM-6-415 expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211002,"accession_number":"0001790340-24-000064","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering reports Q2 net loss $14.1M; Fast Track for IMM-1-104; initial Phase 2 data expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.1M ($0.47/share) vs $12.2M ($0.43) in Q2 2023.","Cash $59.7M as of June 30, 2024; expected cash runway into 2H 2025.","FDA granted Fast Track designation for IMM-1-104 in first-line pancreatic cancer.","Initial data from multiple arms of IMM-1-104 Phase 2a trial expected in 2H 2024.","Initial PK/PD/safety data for IMM-6-415 Phase 1 expected in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229489,"accession_number":"0001790340-24-000060","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immuneering stockholders re-elect Carpenter, Zeskind as Class III directors; ratifies RSM US LLP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert J. Carpenter elected with 11,180,033 votes for, 3,731,579 withheld; 5,694,645 broker non-votes.","Benjamin J. Zeskind elected with 14,395,855 votes for, 515,757 withheld; same broker non-votes.","Ratification of RSM US LLP as auditor for FY2024: 20,337,444 for, 38,268 against, 230,545 abstain.","Approximately 69.5% of outstanding Class A common stock represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229488,"accession_number":"0001790340-24-000058","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immuneering reprices underwater employee stock options to $3.01 with retention restriction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repricing applies to options with exercise price >$3.01 held by employees and certain service providers; excludes CEO, CSO, and non-employee directors.","Exercise price reduced to $3.01 per share (approx. 2x May 21 closing price).","Repriced options revert to original exercise price if exercised before June 30, 2025, unless change of control or qualifying termination.","Repricing intended to retain and motivate employees without additional equity grants or cash outlays.","Total number of repriced options not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229487,"accession_number":"0001790340-24-000054","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.","Phase 1 data for IMM-1-104 shows well-tolerated safety; target lesion regression in >50% of patients at 320mg.","First patient dosed in Phase 2a of IMM-1-104; initial data from multiple arms expected in 2024.","First patient dosed in Phase 1/2a of IMM-6-415 (RAF/RAS mutations); initial PK/PD/safety data expected 2024.","FDA Fast Track designation for IMM-1-104 in pancreatic cancer; cash $71.3M expected to fund operations into H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248032,"accession_number":"0001104659-24-034204","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Immuneering doses first patient in Phase 2a of IMM-1-104; Phase 1 data shows safety and biomarker activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 2a of IMM-1-104; ~150 patients planned across 5 arms (monotherapy and combination).","Phase 1 (N=41): no grade 4 TRAEs; only one grade 3 (reversible rash); most common grade 1/2: diarrhea 19.5%, nausea 19.5%.","At 320mg, pERK inhibition ≥90% for 2.7h; 100% of evaluable patients (N=22) showed no new RAS or MAPK pathway mutations by ctDNA.","53% of patients had ≥1 target lesion regression at 240/320mg; best individual regression -35.7% at 320mg in second-line.","Thomas J. Schall, Ph.D. appointed to Board of Directors as Class I Director effective March 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248031,"accession_number":"0001790340-24-000022","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immuneering reports $85.7M cash, net loss $53.5M in 2023; trial milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $85.7M as of Dec 31, 2023; cash runway into 2H 2025.","Net loss Q4 2023 $15.1M ($0.52 per share); full year net loss $53.5M ($1.88 per share).","FDA Fast Track designation for IMM-1-104 in pancreatic cancer received Feb 2024.","Topline Phase 1 data for IMM-1-104 expected March 2024; first patient in Phase 2a expected March 2024.","First patient dosing in Phase 1/2a trial of IMM-6-415 expected March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248030,"accession_number":"0001104659-24-010041","cik":1790340,"company_name":"Immuneering Corp","ticker":"IMRX","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Immuneering amends bylaws to address universal proxy rules and enhance stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaw amendments require compliance with SEC Rule 14a-19 for proxy solicitations supporting director nominees.","Enhanced disclosure requirements for stockholder director nominations and other business proposals, including ownership and relationship details.","Stockholders soliciting proxies from other stockholders must use a proxy card color other than white.","Amendments effective February 1, 2024; include technical and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":340896163.6794939,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}